The SETS aHUS trial, led by Professor Neil Sheerin, has been published here in The Lancet Regional Health Europe.
This trial looked at whether Eculizumab could be stopped in some aHUS patients without causing any harm to them.
The results from this clinical trial are very encouraging, demonstrating that it was as safe to stop treatment as continuing with Eculizumab, provided patients were adequately monitored and knew what to do in the case of suspected aHUS relapse.
We are currently in discussion with NHS England about what the trial findings mean for aHUS patients, and we will be in touch with all of our patients on treatment over the next few months to discuss the trial, and what the results mean for them.
